GeneralConnection.com ➔ Dictionary
Dictionary Search

lutetium

Synonyms

Noun

1. lutecium

2. Lu, atomic number 71, metallic element, metal

Usage
PSMAddition Trial of ADT, ARPI, and Lutetium-177 in Metastatic Hormone-Sensitive Prostate Cancer - Fred Saad - UroToday
Curium, Lantheus win patent dispute over lutetium-177 dotatate products - AuntMinnie
Lutetium Lu 177 Vipivotide Tetraxetan Provides rPFS Benefit in mHSPC Regardless of Disease Volume or De Novo/Recurrent Status - OncLive
Convo-1α Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy - HMP Global Learning Network
PROSTest mRNA Assay Tested for Response Prediction to Lutetium PSMA in mCRPC - Mark Kidd - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Triplet Shows Consistent rPFS Benefit Across Disease Volume and mHSPC Status Subgroups - OncLive
MURR makes NCA Lu-177 available worldwide - Show Me Mizzou
Lutetium-177-PSMA-617 in First-Line mHSPC and Its Impact on PSA Depth, Undetectable Rates, and Time to Progression - Fred Saad - UroToday
Lutetium Lu 177 Dotatate Radioequivalent Receives Tentative FDA Approval for SSTR+ GEP-NETs - OncLive
Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT/ARPI Improves Frequency, Depth of PSA Responses in PSMA+ mHSPC - OncLive
Combination Approaches in Lutetium PSMA Therapy in mCRPC - Michael Hofman - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT and an ARPI Maintains QOL in mHSPC - OncLive
Adaptive Dosing of Lutetium PSMA Based on Imaging and PSA Response - Louise Emmett - UroToday
Lutetium Lu 177 Vipivotide Tetraxetan Remains Effective After Sipuleucel-T in mCRPC - OncLive
APCCC 2026: How to Make Best Use of Lutetium-PSMA Radioligand Therapy? - UroToday
Lutetium-177 Rosopatamab Tetraxetan Plus SOC Meets Primary Safety End Point in PSMA+ mCRPC - OncLive
APCCC 2026: How to Optimally Select Patients for Lutetium-PSMA Radioligand Therapy? - UroToday
Real-World Analysis of Lutetium-177 in mCRPC by Taxane Treatment Sequence - Micah Ostrowski - UroToday
Racial Differences Do Not Affect PSA Response With Lutetium Lu-177 Vipivotide Tetraxetan in mCRPC - OncLive
The PLUDO Study: Comparing First-Line Lutetium vs Docetaxel in Chemo-Naive Metastatic Prostate Cancer - Kim Chi - UroToday
Lu-177 PSMA-SPECT/CT predicts survival in mCRPC - AuntMinnie
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177–PSMA-617 - Wiley
Prior Radium-223 Does Not Affect Cancer-Control Outcomes With Lutetium-177-PSMA in mCRPC - Cancer Therapy Advisor
Raul Tirinescu: Timing of Lutetium-177 PSMA Therapy in Prostate Cancer Treatment - Oncodaily
Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177 - Cision News
First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer - BioSpace
UCLA Health launches novel clinical trial for recurrent prostate cancer - UCLA Health
Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand - BioSpace
Telix advances PSMA radiotherapy challenger to Pluvicto - BioWorld News
Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis - Journal of Nuclear Medicine
Novartis pulls bid to broaden Pluvicto use after EU pushback - FirstWord Pharma
LSR: Dysprosium, terbium and lutetium in xenotime... huh? The market liked it. - Next Investors
Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database - Nature
Radioligand Therapy Market Size, Share, Growth, Analysis, 2034 - Straits Research
Korea Localizes Production of Lutetium-177, a Radioisotope with a ₩2 Trillion Global Market - 동아사이언스
Worthing prostate cancer patient receives cutting-edge therapy - BBC
New theranostic pairing shows promise for upper gastrointestinal tumors - AuntMinnie
ESMO backs lutetium therapy in updated prostate cancer guideline - the limbic
PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management - OncLive
Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma - OncLive
Dr Tagawa on the Efficacy of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC - OncLive
Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC - OncLive
PSMACare: Early Lutetium RLT in High-Risk nmCRPC - Fred Saad - UroToday
Integrating Lutetium-177-PSMA-617: Sequencing, Combinations, and Safety in Taxane-Naïve mCRPC - Michael Morris - UroToday
FDA approves earlier use of lutetium Lu 177 vipivotide tetraxetan for patients with PSMA-positive metastatic castration-resistant prostate cancer - Mayo Clinic
Lutetium-177 PSMA-617 Delays Progression in Early-Stage Prostate Cancer - Targeted Oncology
Lutetium Lu 177 Dotatate Yields Partial Responses in Metastatic Bronchopulmonary Neuroendocrine Tumors - OncLive
LUNAR Trial: Neoadjuvant Lutetium-PSMA Plus SBRT Evaluated in Oligometastatic Prostate Cancer - Amar Kishan & Jeremie Calais - UroToday
Lutetium 177 Market Size, Share and Trends Report 2025 to 2034 - Insightace Analytic
Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer - CancerNetwork
Dr Chi on Potential Prognostic Markers for Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC - OncLive
Phase II LUNAR Trial Results: Adding Lutetium PSMA to SBRT for Oligorecurrent Prostate Cancer - Amar Kishan - UroToday
Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma - OncLive
Interim PSMAddition Analysis Shows Lutetium PSMA-617 Improves rPFS in mHSPC - Scott Tagawa - UroToday
Lutetium-177 PSMA-617 Plus ADT and ARPI Improves Progression-Free Survival in PSMAddition Trial - Pharmacy Times
Safety and Dosing of Lutetium-PSMA in the Pre-Chemotherapy PSMAfore Trial - Oliver Sartor - UroToday
The isotope’s journey - Show Me Mizzou
Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy - OncLive
Access to Lu177-PSMA for Prostate Cancer: From Clinical Trials to the Real World - ASCO Daily News
Lutetium-177 With RT Prolongs Survival in Prostate Cancer - Medscape
Dr Tagawa on Factors for Lutetium Lu 177 Vipivotide Tetraxetan Use Before Docetaxel in mCRPC - OncLive
Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor - UroToday
ASCO 2025: How to Get Lutetium-177 PSMA to Those That Will Most Benefit? - UroToday
EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA Improves mCRPC Outcomes - Shahneen Sandhu - UroToday
Lutetium and hafnium tell the story of liquid water on asteroid Ryugu - Physics Today
Dr Tagawa on the PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC - OncLive
First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Journal of Nuclear Medicine
Dr Tagawa on the Safety Profile of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC - OncLive
Variability in Clinical Practice of Lutetium-177 Therapies - Journal of Nuclear Medicine
Kim Chi, MD, discusses the PR.21 study of lutetium vs docetaxel in mCRPC - Urology Times
Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resistant Prostate Cancer "Presentation" - Michael Hofman - UroToday
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC - Urology Times
A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents - Nature
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer - The New England Journal of Medicine
Feasibility of Multi-Peak Acquisition Strategies for Rapid Quantitative Lutetium-177 SPECT/CT - Journal of Nuclear Medicine
FDA Expands Indication for Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC - OncLive
Dysprosium, cerium, indium, yttrium, and lutetium as emerging contributors to oxidative stress in polycystic ovary syndrome - Nature
Lutetium Lu 177 Vipivotide Tetraxetan Generates rPFS Improvement in PSMA+ mHSPC - OncLive
SUVmean on PSMA PET Predicts Lutetium-PSMA Therapy Success in mCRPC - Koichiro Kimura - UroToday
Terbium-161 vs Lutetium-177: Comparing Next-Gen Radioligands for Prostate Cancer - Michael Hofman - UroToday
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann - UroToday
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC - OncLive
Actinium-PSMA J591 After Prior Lutetium Therapy in Metastatic Prostate Cancer - Scott Tagawa - UroToday
Microscopic theory of colour in lutetium hydride - Nature
Overall Survival With Lutetium 177 May Be Impacted by Subsequent Therapies, Prognostic Risk Groups in mCRPC - CancerNetwork
FDA Receives 505(b)(2) NDA Seeking Approval for Lutetium Lu 177 Dotatate - Targeted Oncology
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett - UroToday
Possible Superconductivity Transition in Nitrogen-Doped Lutetium Hydride Observed at Megabar Pressure - Wiley
Rapid xSPECT/CT Post Treatment Whole Body Imaging Following Lutetium DOTATATE and Lutetium PSMA Therapies - Journal of Nuclear Medicine
Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data - PR Newswire
Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs - UroToday
Personalizing Lutetium-177 Dosing: The FLEX-MRT Trial Approach - Adrien Holzgreve - UroToday
Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber - UroToday
New CRP: Development of Potential Lutetium-177 Radiopharmaceuticals: Design, Radiolabelling and Nonclinical Evaluation (F22078) - International Atomic Energy Agency
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett - UroToday
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi - UroToday
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial - Journal of Nuclear Medicine
Real-World Treatment Delays Between Lutetium-177 and Cabazitaxel in Advanced Prostate Cancer - Yeonjung Jo & Umang Swami - UroToday
Real-world Experiences Associated with Treating Patients With Lutetium-177 PSMA in a High-volume Care Center - Thomas Hope - UroToday
Foreign Language Equivalents
Foreign Language Equivalents of 'lutetium'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
lutteium,   lutettium,   lutwtium,   lutetiim,   ultetium,   lytetium,   luteyium,   luttium,   lutetiym,   ltetium,   luetium,   lutetuum,   lutetiu,,   luteium,   lutetim,   litetium,   luttetium,   ;utetium,   ltuetium,   lutetum,   lutetiuum,   lutetimu,   lutetiun,   lutrtium,   lutetiumm,   luyetium,   luterium,   llutetium,   luteetium,   kutetium,   lutetiium,   utetium,   luretium,   lutetiu,   luteitum,   lutetoum,   luettium,   luutetium,   lutetuim
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z